Magnetocardiographic Rotation Score and Arrhythmic Endpoints in Primary-Prevention ICD Recipients: An Exploratory Substudy of the Magneto-SCD Trial
Authors:
- Thomas LachlanTLThomas Lachlan
- Hejie HeHHHejie He
- Adam MillerAMAdam Miller
- Nakul ChandanNCNakul Chandan
- Taesoon HwangTHTaesoon Hwang
- Shoaib SiddiquiSSShoaib Siddiqui
- Roger BeadleRBRoger Beadle
- David WilsonDWDavid Wilson
- Sanjiv PetkarSPSanjiv Petkar
- Ven Gee LimVLVen Gee Lim
- Peter K. KimaniPKPeter K. Kimani
- Faizel OsmanFOFaizel Osman
Open Access
- 9 September 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6985
Abstract
Background/Objectives: Primary-prevention implantable cardioverter-defibrillator (ICD) selection remains dominated by left ventricular ejection fraction and clinical heart failure markers, which incompletely distinguish between patients who will experience ventricular arrhythmia and those whose prognosis is limited by competing non-arrhythmic mortality. The Magneto-SCD trial recently reported novel rotation-based magnetocardiography (MCG) indices associated with future appropriate ICD therapies. This substudy explores whether MCG Rotation Score provides incremental information in primary-prevention ICD recipients, particularly beyond NYHA status and MADIT-arrhythmic and non-arrhythmic risk scores. Methods: We included all Magneto-SCD trial participants with a primary-prevention indication with non-missing follow-up/MCG Rotation Score data. The full primary-prevention cohort comprised 54 participants; the post-MI subgroup comprised 28. The primary endpoint was time to first appropriate ICD therapy. Death without prior therapy was used as a pragmatic competing endpoint and not assumed to represent adjudicated non-arrhythmic death. Appropriate shock was a secondary endpoint. Two-year cumulative incidence functions were estimated using Aalen–Johansen methods. Cause-specific Cox models assessed Rotation Score alone and after addition to MADIT-derived scores; nested likelihood-ratio tests evaluated model fit. Results: Of 104 participants, 90 had analysable MCG data and 65 had a primary-prevention ICD indication; after exclusions for missing patients, 54 patients remained (mean age 63.8 ± 13.2 yrs, 45(83.3%) male). Appropriate ICD therapies occurred in 10 (18.5%), including appropriate ICD shock in eight (14.8%); 10 patients (18.5%) died without prior therapy. The median follow-up was 1211.5 days (IQR 793.5–1396.0). Each SD increase in Rotation Score was associated with appropriate ICD therapy with HR 1.64 (95% CI 0.93–2.87; p = 0.086), appropriate ICD shock with HR 2.07 (95% CI 1.15–3.72; p = 0.015), death without prior therapy with HR 1.08 (95% CI 0.54–2.17; p = 0.824), and death without prior ICD shock with HR 0.95 (95% CI 0.48–1.90; p = 0.890). Adding Rotation Score did not significantly improve the primary therapy model beyond MADIT components (LRT p = 0.065) or MADIT benefit score (LRT p = 0.109). Model fit improved for the secondary appropriate ICD shock endpoint when Rotation Score was added to MADIT components (LRT p = 0.016), based on eight shock events. Conclusions: Rotation Score showed an association pattern more closely aligned with arrhythmic endpoints, particularly appropriate ICD shock, than with death without prior therapy. Incremental prognostic value for the primary endpoint was not established. These findings are hypothesis-generating and require confirmation in adequately powered, prospectively designed and externally validated cohorts before any role in clinical risk stratification or ICD decision-making can be determined.Keywords
Funding Information
- Creavo Medical Technologies
This publication has 24 references indexed in Scilit:
- MAGNETOcardiography Parameters to Predict Sudden Cardiac Death (MAGNETO-SCD) or Ventricular Events From Implantable Cardioverter DefibrillatorsJACC: Clinical Electrophysiology, 2026
- Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trialAmerican Heart Journal, 2025
- PRevention of sudden cardiac death aFter myocardial infarction by defibrillator implantation: Design and rationale of the PROFID EHRA randomized clinical trialAmerican Heart Journal, 2025
- Alert Transmissions From Remote Monitoring of Patients With Cardiac Implantable DevicesJACC: Clinical Electrophysiology, 2023
- Treatment with gentamicin-impregnated collagen sponges in reducing infection of implantable cardiac devices: 10-year analysis with propensity score matchingRevista Portuguesa de Cardiologia, 2023
- Feasibility of novel unshielded portable magnetocardiography: Insights from the prospective multicenter MAGNETO-SCD trialHeart Rhythm, 2022
- Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated CardiomyopathyJACC: Heart Failure, 2017
- Defibrillator Implantation in Patients with Nonischemic Systolic Heart FailureNew England Journal of Medicine, 2016
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002